Wide Ranks

CNSP

CNS Pharmaceuticals, Inc.

0.1154

Top Statistics
Market Cap 6 M Forward PE -0.2959 Revenue Growth 0.00 %
Current Ratio 0.32 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.1260 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 1 M Total Cash Per Share 0.0460 Total Debt 123248
Total Debt To Equity Current Ratio 0.32 Book Value Per Share -35.66
All Measures
Short Ratio 4.00 % Message Board Id finmb_555951193 Shares Short Prior Month 678968
City Houston Uuid d5944f40-c6d8-36ac-a359-a17d6936eb31 Previous Close 0.1164
First Trade Date Epoch Utc 1 B Book Value -35.66 Beta 1.05
Total Debt 123248 Volume 1 M Last Split Date 1 B
Fifty Two Week Low 0.0960 Total Cash Per Share 0.0460 Shares Short Previous Month Date 1 B
Target Median Price 0.5000 Max Age 86400 Recommendation Mean 2.00
Sand P52 Week Change 0.3133 Target Mean Price 0.5000 Net Income To Common -15973546
Short Percent Of Float 0.0279 Implied Shares Outstanding 57 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 9 M Average Volume10days 9 M
Total Cash 1 M Next Fiscal Year End 1 B Held Percent Insiders 0.0104
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 0.1164 Target Low Price 0.5000 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.1265 Open 0.1179 Free Cashflow -5190236
State TX Dividend Yield 0.00 % Return On Assets -2.24
Time Zone Short Name EST Trailing Eps -299.06 Day Low 0.1134
Address1 2100 West Loop South Shares Outstanding 57 M Price Hint 4
Target High Price 0.5000 Website https://www.cnspharma.com 52 Week Change -0.9989
Average Volume 15 M Forward Eps -0.3900 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 22.10 % Last Split Factor 1:50
Regular Market Day High 0.1179 Is_sp_500 False Profit Margins 0.00 %
Fifty Two Week High 114.50 Day High 0.1179 Shares Short 1 M
Regular Market Open 0.1179 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0279 Operating Cashflow -10755122
Currency USD Time Zone Full Name America/New_York Market Cap 6 M
Is_nasdaq_100 False Zip 77027 Quote Type EQUITY
Industry Biotechnology Long Name CNS Pharmaceuticals, Inc. Regular Market Day Low 0.1134
Held Percent Institutions 0.0079 Current Price 0.1154 Address2 Suite 900
Enterprise To Ebitda -0.1260 Financial Currency USD Current Ratio 0.32
Industry Disp Biotechnology Number Of Analyst Opinions 1 Country United States
Float Shares 31 M Two Hundred Day Average 5.65 Enterprise Value 2 M
Forward PE -0.2959 Regular Market Volume 1 M Ebitda -15982778
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.

The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.

CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.

D.

Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.